Member Info for Hulver

When a large tree falls in the forest it leaves room for a small one to grow!

Here's what FierceBiotech reported at the time of the Gilead-FortySeven deal (back in 2020):

https://www.fiercebiotech.com/biotech/gilead-strikes-4-9b-forty-seven-acquisition-paying-a-hefty-premium-for-cancer-drug

So does this suggest:

(i) CAR-T is going to be the solution rather than bi-specific antibodies as they can't seem to get antibodies to work to the required degree/specificity; and/or

(ii) CDX ab, which I think it was hoped would have multiple applications, and so similar to Magrolimab - might attract renewed interest as a potential ab to fill the 'Magromilab' space; and/or

(iii) big pharma are going to be more cautious in valuing mid-phase acquisitions, so it may be harder to get a licensing deal for either product.

I like the teaser - 'could their be renewed interest in CDX' ? - best.

It's a good job work has been continuing on it in the background - Elina mentioned CDX and it moving towards clinical trials in the 'HEMO 2023' video link I posted yesterday.

Very interesting times.

Can't grow without investment.

Future stock and dilution => we have success product development => we have successful company.

The pathway is clear; Feldmann said the science is good.

There's room to grow - plenty room and in multiple directions.

The people (below) seem to have little doubt as to why they have chosen Hemogenyx:

https://www.youtube.com/watch?v=4u9NRLi67oE

Michael Haugbro (ex Princeton):

"...decided after I graduated to join industry and at the time I found Hemogenyx and I though it was a very exciting opportunity in, really, a company that was uniquely situated to have a large impact in the immune oncology field."

Jessica Jang (ex Celgene, Cellectis):

"At Hemogenyx my current project focuses on differentiation of macrophages from either haematopoietic stem cells or blood monocytes so we can re-engineer these macrophages to express the Chimeric Bait Receptor and treat infectious diseases. The platform will hopefully allow us to expand to other diseases such as cancer and solid tumours. I am really excited about the project because I think it has the potential to be used in many different diseases, not just infectious diseases."

Ronen Ben Yehuda (Principal Scientist): (in relation to CBR, and SARS-COV-2)

"we are about to start BSL-3 facility experiments in order to test our constructs in vivo in mice and for that we will be using a live replicating virus, and as always we will share our results and news with you"

Elina Shrestha (Director of Preclinical Studies):

"..our team dynamics is incredible and this is a true reflection of Hemogenyx's core values in team building and team evolution."

......but maybe you know better.

PS: Posted the link as I couldn't see it on the company's website - video section! It was released June 2023 just prior to the AGM. Worth a listen through to the very last contribution.

Did cross my mind today whether they might release early as new share issue happening on or around 29th - and the report might need to contain the up to date numbers which would entail late changes and proofing. Maybe other news is also due that would impact interim report and disclosures. Let's see.

RESI Boston September Innovator's pitch winners:

1. Light Line

2. Able Labs (seemingly also on a disease x solution pathway)

3. Gliachem

so unfortunately HEMO or its alias Bait | 0 Technology not a winner this time (out of 52 that pitched) - but still represented and presumably gaining visibility.

Is HEMO's ladder leaning against the right wall? It seems so based on the results/advancement of others whose work also targets the FLT-3 mutation:

https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-vanflyta-aml-flt3

"As long as the person is well enough to receive the intensive chemotherapy included in the treatment, Dr. Erba said, the addition of quizartinib “should become the standard of care for patients with FLT3 ITD-positive AML.”"

- that's until HEMO CAR-T for FLT-3 (and no chemotherapy required)

Two thoughts:

(i) on that basis, those that got in on the 'unexpected' 2.5p issue of shares (at the time this 6p valuation was being determined, if that was back in January) were even smarter, or....................? We might find the 2.5p share issue to be mostly, if not all, in sticky hands and therefore not that much selling between 2.5p and 3p? Hopefully not like the 1.5p issue.

(ii) due to the delay did they get to the point that this 6p deal had to be announced now because a new valuation (including CBR progress uplift) is being determined for further new 'CBR' 'Bait| OTechnology' investors ? Or does the 6p include adjustment for CBR progress uplift - since announcement suggested agreement of terms was only reached last Friday.

Note (end of today's RNS) that the new shares are expected to be admitted on 29th September.

? is that to coincide with the date of the issue of the interims, and our next full update!?

Will that RNS contain the CBR development and in vitro testing update? Looking good to me.

Simon, that's 6p for an investor potentially based of status of HEMO-CAR-T only.

Meanwhile - Vlad's off promoting CBR to potential investors today - undercover as Bait| 0Technology! - because it's ready for new investment too!

The fountain is breaking.

Clears the way for Vlad, whilst masquerading as Bait| OTechnology next week, to discuss the current status of HEMO CAR-T with people who know of Hemogenyx and its broader pipeline/plans.

There was no need to update this at this point, maybe this is an indication of more communications as requested at the AGM. If so great. All plates still spinning - perhaps we'll get further updates on the others soon too.

This is the lab HEMO is working with on its HEMO CAR-T, targeting FLT3.

https://www.pennmedicine.org/news/news-releases/2023/august/an-immunotherapy-strategy-against-all-blood-cancers

Would this epitope editing approach seem to be a good fit for HEMO CAR-T as the FLT3 ligand is found on progenitor cells that recreate the blood, So rather than targeting and replacing all blood cells......would this type of tech adaptation in HEMO CAR-T enable a more focused solution with less adverse impact on the patient? Is anyone with scientific knowledge able to comment?

Further dilution ......... or necessary investment (to get to the science goal with the investment rewards that may follow) - that depends on your viewpoint.

So the pitch day is Monday 18th September in person.

4 minutes pitch

8 minutes Q&A

Followed by two days for any 'interested investor' meetings (virtual it seems).

The following investor pitch webinar 11:30 (ish) to 30 minutes gives an outline of what should be included in the presenation.

https://www.youtube.com/watch?v=5Go8oyPm6wY&feature=youtu.be

Shame we can't attend - if we could, judging by the suggested content (and let's hope Vlad has paid attention), we might find out what is going on - eg next steps, competitors, differentiates, patent plans, timelines etc.

Anyway all seems positive to me. Awareness of HEMO is expanding.

Does this increase teh likelihood that they will issue news on CBR before, at the sane time as, or after the pitch .

Does it mean CBR is ready for further investment for the next stage of its testing/development?

This 'Bait-OTechnology' is on the list of attendees but when you click on it - it brings up HEMO website.

https://resiconference.com/pitch-challenge/

separate entity formed or just a cover for CBR.

Https://www.linkedin.com/posts/life-science-nation_investor-resibos-resiboston-activity-7106011664025571328-a3Uc?trk=public_profile_like_view

thoughts?

Saint / Trift

From my post 10 Aug:

'We were told about the submission by RNS on 16/03/22. It lasts for 12 months, after which Vlad (at that time) indicated that they would then switch it to an International patent; and shortly after that switch it would become publicly available for all to read (he suggested that would be around 18 months from the original application - March 22?). I think he indicated at the AGM that the patent would be publicly available around August time. He gave the impression that publication was not a concern - as things had moved on a lot since that. '

So I think the date 01/03/22 is the original US patent application and the date 01/03/23 is the date of the International Patent application. I think the link that HT provided evidenced it now as being an International Patent application.

I take this as either neutral or positive depending on what their testing had shown by 01/03/23 (maybe not a lot by that time); but if testing results had been negative or problems identified by then- then would they still have committed to switching it to an International Patent? But I think the link shows that they did make that switch.

Perhaps someone with knowledge of patent applications could confirm.

At the AGM PR said that everyone's aims were aligned here - but I find it concerning that they seemed not to be going to RNS this had it not been discovered.

Great question.

I'm hoping we might next see [3 with 4] together, before or maybe even alongside interims.

then 1, 2, 5.

Those we know are ongoing, but could there be a '6 - Unexpected News of Something Else' to slot in somewhere?

Gilead struggling with their Magrolimab trials:

https://www.targetedonc.com/view/fda-pauses-magrolimab-studies-in-acute-myeloid-leukemia

Increasing interest in HEMO's CDX antibody?

Also note their first clinical hold on Magrolimab Jan 22 was lifted Apr 22.

Their clinical hold on Lenacapavir (HIV) Mar 22 was lifted May 22